Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYGN 18.18 +0.20(1.11%)
Will MYGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Myriad Genetics (MYGN) Announces Favorable Research Results
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Other News for MYGN
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Myriad Genetics announces new study published in Prenatal Diagnosis
MYGN Makes Notable Cross Below Critical Moving Average
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing